2 1 Shi Ji Jing Ji Bao Dao·2025-05-08 01:56Group 1 - The Hong Kong stock market opened lower on May 8, with the Hang Seng Index down 0.45% and the Hang Seng Tech Index down 0.28%, while the Hong Kong Innovation Drug Index rose by 0.18% [1] - The Hong Kong Innovation Drug ETF (159567) opened higher and increased by 1.16%, with notable gains in component stocks such as Ascentage Pharma-B up over 3% and Lepu Biopharma-B up over 2% [1] - The Hong Kong Innovation Drug ETF closely tracks the Hong Kong Innovation Drug Index, which reflects the performance characteristics of biotechnology companies listed under the Hong Kong Stock Connect [1] Group 2 - According to Everbright Securities, the commercialization of domestic weight-loss drugs is imminent, and sales capabilities will be a significant factor in assessing future competitive advantages for companies [2] - China Galaxy Securities noted that the pharmaceutical sector has experienced a prolonged adjustment, with overall valuations at low levels and public fund holdings underweight, suggesting a potential recovery in the pharmaceutical market in 2025 [2] - Cinda Securities anticipates that the second quarter of 2025 may see catalysts for innovative drugs, including expected negotiations for medical insurance and the implementation of the Class B medical insurance directory [2]